| 摘要 |
<p>Disclosed is a method for predicting the therapeutic effect in the treatment of chronic hepatitis C by a combination therapy using pegylated interferon and ribavirin. The method is characterized by comprising a drug sensitivity marker detection step of detecting a drug sensitivity marker in a biological sample and a drug sensitivity evaluation step of evaluating the drug sensitivity of the biological sample based on the expression level of the drug sensitivity marker, wherein the biological sample is cells or tissues derived from the liver, and the drug sensitivity marker comprises at least one microRNA selected from the group consisting of the microRNA molecules represented by SEQ ID NO:1 to SEQ ID NO:37.</p> |
